Gout being sneaky🧐 Common consult question is "infection or flare?" in patients with gout. @ACR21 ABS0467 w/ Dr Michael Toprover: 🔸Calibrating DECT for LS-spine in gout patients. 🔹DECT signal = MSU deposition? 🔸Future data on back pain/gout flare/MSU🤞? @RheumaRepublic https://t.co/aDCusqBk8G

Important #gout study (I'm biased): allopurinol is non-inferior to febuxostat with regards to gout flare when used in a T2T approach, with no differences in AEs, including CV risk. 99% achieved serum urate target over course of trial. Key slides following. #ACR21 https://t.co/tWeGvZ4rKY

We may be getting a new urate lowering therapy. Tigulixostat is a non-purine selective xanthine oxidase inhibitor. Nothing worrying on safety. But I think febuxostat is probably more effective than this? Abstr#L05 #ACR21 @RheumNow https://t.co/Lg0slMlah2

Advantages of treat to target (of serum urate) beyond less gout flares? Maybe equal to ⬇️MACE events - I hope in long term less MACE due to less ⬆️CRP w flares. Modelling observational study abst#L06 #ACR21 #ACRBest @RheumNow below is comparative safety T2T better than usual care https://t.co/95M6lNX416

#ACR21 L05. Tigulixostat - non-purine selective XO inhibitor for gout ⭐️Effectively brought down serum uric acid <5, dose-dependent ⭐️10% pts gout flare with urate lowering @Rheumnow https://t.co/LgwkAQ1wg8 https://t.co/G8CxdGcVOQ

• https://bit.ly/2Yt45oD

#ACR21 L06 Comparative Safety of Gout "Treat-to-target" and "Usual Care" Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach https://t.co/4qo49lpBrt Video interview (https://t.co/k8PHCPaF1r) https://t.co/D4G2Ylkelm

• Comparative Safety of Gout &quot;Treat-to-target&quot; and &quot;Usual Care&quo…
• Kazuki Yoshida, ScD: Gout Treatment Strategies Regarding Cardiovascular Outcomes

8M415 Gout Imaging Advances: Ralf Thiele on US🔊and DECT US>DECT: DECT needs a minimal density of MSU; DCS, tophi <2mm, liquid tophi may not be detected; US can show hyperemia DECT>US: DECT can show areas that may be overlooked from standard protocols 💡Bonus:stay around for Q&A https://t.co/G7yQaj9fHw

Dr Stewart @TonyMerriman2 report in 16,000 patients that repeat serum urate testing not superior to single measure in predicting incident gout over 9 years. Makes sense in general, maybe different in those with medication changes etc? Abstr#1449 #ACR21 @RheumNow https://t.co/69NofMNuB8

Rush on over to ‘DASH’ diet to ⬇️women at risk for gout abst#0991 #ACR21 @RheumNow it is low salt diet and ⤵️serum urate and HTN https://t.co/smQgVpV3BD

In general low health literacy has ⬆️association with non adherence in chronic disease Rx including gout prevention but many other reasons for non adherence cross the health literacy divide. Ex use of alternative Rx, denial, side effects, advice from non HCPs #ACR21 @RheumNow https://t.co/mIIndW1FnV

• Eric Dein on Twitter: &quot;#ACR21 Rheum Secrets and Pearls&#10;Is it Allopurin…

#ACR21 Rheum Secrets and Pearls Is it Allopurinol or adherence concern? Oxypurinol can be helpful in measuring adherence! Kolfenbach: "I despise the term non-compliant patient." Address the many reasons why adherence may be low! Health literacy is key. @Rheumnow https://t.co/CPJ8kvqcCm

DECT (dual energy CT) very helpful to distinguish gout from other crystals and give volumetric measurements using color-coded images... So do we need to do arthrocentesis to diagnose gout anymore? #ACR21 https://t.co/kn2IpXP870

Pearls on gout: 👉Gouty tophi can appear in the L spine and destroy the facet joints #ACR21 Radiology Bootcamp with Dr. Brindle. https://t.co/ml2uI9f10v